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Abstract
Purpose Small cell carcinoma of esophagus (SCEC) is characterized by high malignancy and early metastasis. Although the
morbidity of SCEC is very low, few studies of patients with SCEC have been conducted in China, there are no sufficient
studies of SCEC conducted and reported in the existing published works, and the choices of treatment remain controversial.
In this work, we aim to study the clinical characteristics of SCEC, and explore the corresponding treatment and prognosis
through retrospective analysis.
Material and Methods The original articles were identified through the leading digital libraries in China in which the terms
“esophagus or esophageal” and “small cell esophageal carcinoma” appeared from 2005 to 2009, 1,176 eligible cases were
reviewed for clinical data. Analysis of survival was conducted using the Kaplan–Meier method, and differences were
compared using the log-rank test.
Results One thousand one hundred seventy-six eligible cases were analyzed; the median age of patients was 57 years, with a
male-to-female ratio of 2.4:1. The number of SCEC accounted for 1.26 % of esophageal cancer treated in the same period. Of
the tumors, 89.7 % were located in mid- and lower thoracic esophagus. The average tumor length was 5.4 cm (0.5–17 cm).
The median overall survival was 11.1 months for all patients. The 1-, 2-, 3-, and 5-year average overall survival rates of 469
patients was 51.1, 25.5, 13.2, 7.9 %, respectively. The median survival time for LD patients who received systemic treatment
was 16.8 m, whereas for those who received local treatment (surgery), the median survival time was 10.1 m; the median
survival time for ED patients who received systemic treatment was 7.4 m, compared with 5.8 m for those who received sole
treatment (chemotherapy or radiotherapy).
Conclusions SCEC is a tumor characterized by high malignancy and early metastasis. Although our retrospective analysis
cannot provide definitive conclusions on the optimal treatment modality for SCEC, however, our results suggest that
systemic treatment combined with surgical resection plays a major role in the therapy of SCEC, systemic therapy may be
an effective approach for the treatment of SCEC, and randomized, prospective, multicenter studies are needed to identify
optimal treatment modalities for SCEC
Keywords Small cell carcinoma . Esophagus . Surgery .
Chemotherapy . Radiotherapy . Prognosis
Introduction
Primary small cell carcinoma of the esophagus (SCEC) is a
rare disease, which was first described in 1952 by
McKeown.1 In a study on more than 9,000 autopsy speci-
mens, McKeown described two cases of esophageal tumors
in post mortem examinations that were morphologically
indistinguishable from the well-known primary small cell
carcinoma of lung. SCEC is characterized by high malig-
nancy, distant metastasis, and poor prognosis. SCEC is
rarely seen with an incidence rate of 0.5–2.4 % among all
primary esophageal malignancies in a given period.2 Only
less than 300 cases have been reported in the literature.3
Treatment protocols have not been well established because
of the paucity of cases and a lack of large studies. In recent
years, the incidence of primary SCEC in China has been
increasing gradually with the development of pathologically
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diagnostic techniques. In this report, we retrospectively
analyzed the clinical manifestations, pathological features,
treatment, and prognosis of SCEC.
Materials and Methods
We identified and collected the articles from CNKI and
Wanfang Databases that are two of the primary digital
libraries providing most comprehensive access to full-text
documents of publications in China. The original articles
were identified with the keywords and topics related to
esophagus or esophageal and small cell carcinoma, and
were published during the period from 2005 to 2009. For
a few cases that were reported more than once, we selected
the data of these cases from their most recent publications
for analysis. All eligible cases were extracted according to a
set of recorded features including age, gender, tumor site,
histology (pure or mixed), tumor stage (tumor–node–metas-
tasis (TNM) stage or Veterans’ Administration Lung Study
Group (VALSG) stage), treatment, and follow-up. Local
treatment consisted of radiotherapy and/or surgery, and
systemic treatment consisted of chemotherapy, radiotherapy,
and/or surgery.
The histological criteria for pulmonary small cell carcinoma
prepared by the World Health Organization (WHO, sixth edi-
tion) were used, and both sole small cell and mixed cell types
were considered. Histochemical and immunohistochemical
staining were determined by argyrophilia and the direct or
indirect presence of common neuroendocrine markers includ-
ing NSE (neuron-specific enolase), Syn (synaptophysin), CgA
(chromograninA), CK (cytoeratin), CD56 (lymphocyte antigen
56), and others.
Currently, no specific staging system for SCEC has been
established. Disease stages were presented according to two
staging systems—the 1997 or 2002 American Joint Commit-
tee on Cancer (AJCC) TNM staging system for esophageal
cancer,4 and the VALSG staging system for primary pulmo-
nary small cell carcinoma (SCC).5 The latter one consists of
two staging categories including limited disease (LD) and
extensive disease (ED). LD is defined as tumor confined
within a localized anatomic region with or without regional
lymph node involvement. ED is defined as tumor outside
locoregional boundaries.6 The choice of employing different
system may depend on the management algorithms adopted.
Follow-up was reported in terms of time. We computed the
mean standard deviation of the continuous variables, where
the differences were compared using the Mann–Whitney or
Kruskal–Wallis test. Categorical variables were compared
using Fisher’s exact or the chi-squared test when appropriate.
Overall survival was calculated as the time from diagnosis to
death or the last follow-up appointment for surviving patients.
Analysis of survival was conducted using the Kaplan–Meier
method, and differences were compared using the log-rank
test. Statistical significance was defined as a p value that was
smaller than 0.05.
Results
A total of 72 original articles on SCEC were published in
China during the selected period in our study. Among these
articles, there were only 30 eligible articles in which the
studies covered 15 provinces and regions of China,7
–36 and
the median time of patients collection was 15 years (range
from 5 to 40 years).
One thousand one hundred seventy-six patients with
SCEC were admitted from these selected 30 articles. The
rate of the patients with esophageal in different provinces
and regions during the time period ranged from 0.36 to
2.8 %, and the median rate was 1.26 %. Among the 1,176
patients, 830 were males and 346 were females. The male-
to-female ratio ranged from 0.44:1 to 5.6:1 across different
provinces and regions of the country, and the median ratio
was 2.40:1. Moreover, the age ranged from 25 to 87 years,
and the median value was 57 years.
Clinical Presentations
We noted that the clinical presentations were dominated by the
advanced stage at the time of diagnosis. Clinical symptoms of
SCEC were similar to that of squamous carcinoma of the
esophagus, and no significant specificity was seen in X-rays
imaging and esophagoscopy.7 we observed that the most
common initial symptoms, such as progressive dysphagia
and anorexia, were shown in almost all patients (ranging from
78.8 to100%). The other symptoms, including retrosternal
pain and swallowing pain, were shown in some advanced
patients, and the rates were 22.8 and 15.6 %, respectively. A
few patients may have hoarse voice and weight loss, etc. The
duration of symptoms before diagnosis varied from 10 days to
20 months, with a mean time of 1 month.
Tumor Characteristics
Tumor characteristics were summarized in Table 1. In par-
ticular, the tumor location varied among the patients. For
most patients (62.2 %, 731/1,176), the tumors were located
in middle of the thoracic esophagus. The tumors were found
in the upper third of the thoracic esophagus for 116 patients
(9.9 %, 116/1,176), and in lower third of the thoracic esoph-
agus for 324 patients (27.6 %, 324/1,176). Only for five
patients (0.4 %), the tumors were found in cervical segment
of the esophagus. The tumor length was measured for most
patients (77.6 %, 912/1,176). The length ranged from 0.5 to
17 cm, and the average value was 5.4 cm.
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Only a small part of the patients (27.4 %, 322/1,176)
were pathologically confirmed to be esophageal cancer by
esophagoscopy and biopsy before operation. Only 74 pa-
tients (6.3 %, 74/1,176) were histologically diagnosed with
SCEC by esophagoscopy and biopsy before operations.
Among the rest of the patients, 62 were pathologically
diagnosed to have poorly differentiated squamous cell car-
cinoma, 24 with poorly differentiated cell carcinoma, and
162 with esophageal squamous cell carcinoma.
Pathological Features
All the patients were diagnosed with SCEC by postoperative
histopathology and a part of patients were applied with im-
munohistochemical staining. The specimens were classified
as pure SCEC in 597 cases (81.2 %, 597/735) and mixed
esophageal cancer in 138 cases (18.8 %, 138/735). Among the
138 cases, there were 123 cases with squamous cell carcinoma
predominance, 12 cases with adencarcinoma, and 3 cases with
adeno-squamous carcinoma.
Immunohistochemical study information was available
for 309 patients. Staining for five immunological markers
(NSE, Syn, CgA, CK, and CD56) was performed on a part
of the cases. Specifically, 87.7 % (268/309) of the immuno-
logical reactivity of the samples were NSE, 75.8 %
(169/223) were Syn, 71.9 % (205/285) were CgA, 40.3 %
(31/77) were CK, and 97.9 % (39/42) were CD56.
Stagings
According to the 1997 or 2002 AJCC TNM staging system,
of 523 cases studied, there were 34 cases in stage I (6.5 %,
34/523), 99 cases in stage IIa (18.9 %), 90 cases in stage IIIb
(17.2 %), 201 cases in stage III (38.4 %), and 99 cases in
stage IV (18.9 %). By VALSG criteria, of 467 patients
studied, 74.3 % (347/467) of the patients had LD, and
25.7 % (120/467) of the patients presented with ED.
Treatment
Since nearly all patients with SCEC were diagnosed as esoph-
ageal squamous cell carcinoma or poorly differentiated carcino-
ma initially, most patients underwent initial surgical resection.
Of the 1,176 patients studied, 936 patients received surgical
resection, in which 885 patients underwent radical resection
and 51 patients with palliative operation. The resection rate
and radical resection rate were 79.6% (936/1,176) and 94.6%
(885/936), respectively. Surgery was the sole treatment mo-
dality in 277 cases where 263 cases with radical and 14 cases
with palliative resection. Adjuvant chemoradiotherapy was
used in 565 cases where 391 cases with four to six courses
of platinum-based combination chemotherapy, 50 cases with
radiotherapy, and 124 cases with chemoradiotherapy, respec-
tively. Other 94 patients did not have the records of adjuvant
chemoradiotherapy after surgery,17
, 18 and the comprehensive
treatment rate was 60.4 % (565/936).
Two hundred eight patients received nonoperative treat-
ment due to advanced disease, in which 55 patients with
chemotherapy, 44 patients with radiotherapy, and 109 patients
with chemoradiotherapy, respectively. Five patients did not
receive any treatment, and another 27patients did not have any
records of treatment information in the articles.19
Prognosis
Of the 1,127 patients studied, the median survival time of
403 patients was 11.1 months (range, 10–15 months).7
, 8, 12,
13, 15, 23, 24, 33 The median survival time of patients with and




Cervical 5 0.4 %
Upper thoracic 116 9.9 %
Middle thoracic 731 62.2 %
Lower thoracic 324 27.6 %




Pure SCEC 597 81.2 %
Mixed SCEC 138 18.8 %
Mixed with squamous cell carcinoma 123
Mixed with adencarcinoma 12
Mixed with adenosquamous carcinoma 3
Immunological marker (n=309)
NSE 268 87.7 % (268/309)
Syn 169 75.8 % (169/223)
CgA 205 71.9 % (205/285)
CK 31 40.3 % (31/77)
CD56 39 97.9 % (39/42)
TNM staging (n=523)
I 34 6.5 %
IIa 99 18.9 %
IIb 90 17.2 %
III 201 38.4 %
IV 99 18.9 %
VALSG stage (n=467)
LD 347 74.3 %
ED 120 25.7 %
NSE neuron-specific enolase, Syn synaptophysin, CgA chromogranin
A, CK cytoeratin, CD56 lymphocyte antigen 56, LD limited disease,
ED extensive disease
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without lymph node metastasis were 8.5 months (range, 7–
10 months) and 14 months (range,13–15 months),
respectively.8
, 15 The median survival time for the LD
patients who received systemic treatment was 16.8 months
(range, 11–38 months), compared with 10.1 months (range,
7.5–12 months) for those who received local treatment
(surgery). The median survival time for the ED patients who
received systemic treatment was 7.4 months (range, 7.2–
8.5months), comparedwith 5.8months (range, 4–7.5 months)
for those who received sole treatment (chemotherapy or
radiotherapy).7
, 9–13, 15, 16, 19 Table 2 showed our detailed
univariate analysis of median survival for SCEC patients.
The 1-, 2-, 3-, and 5-year average overall survival rates of
469 patients were 51.1 % (range, 41.3–67.2 %), 25.5 %
(range, 16.1–38.5 %), 13.2 % (range, 6.4–23.3 %), and
7.9 % (range, 3.5–12 %), respectively.7
, 8, 13–15, 18, 23, 24, 33
The 1-, 2-, and 3-year survival rates for the patients with
lymph node metastasis were 31.1 % (range, 26.3–35.9 %),
11.4 % (range, 5.2–17.6 %), and 5.3 % (range, 0–10.6 %),
respectively. The 1-, 2-, and 3-year survival rates for patients
without lymph node metastasis were 77.3 % (range, 75–
79.6 %), 42 % (range, 33.3–50.7 %), and 28.6 % (range,
16.6–40.6 %), respectively.7
, 8 The 1-, 2- and 3-year survival
rates for the LD patients were 62.1, 28.3, and 12.5 %, respec-
tively, compared with 39.5, 8.2, and 0 % for the ED patients.7
,
8 The 1-, 2- and 3-year survival rates for the patients who
received systemic treatment were 69.8, 38.1, and 22.9 %,
respectively, whereas for those who received local treatment
(surgery), the 1-, 2-, and 3-year survival rates were 28.9, 1.9,
and 0 %, respectively.8
, 14 Table 3 showed our detailed
univariate analysis of survival rate for SCEC patients.
Discussion
Since the first description of small cell carcinoma in the
lungs (SCLC) reported in 1926 and the first description of
extrapulmonary small cell carcinoma (EPSCC) in 1930,
small cell carcinoma has been observed in many locations
within body, and the sites cited so far include the head and
neck, esophagus, stomach, pancreas, gallbladder, uterine
cervix, kidney, urinary bladder, and prostate. In a few cases,
the primary site remains undetected, which has been identi-
fied as small cell carcinoma of unknown origin.37
–39 Nearly
half of the cases reported in the literature were located in the
esophagus.39
, 40 In contrast to SCLC that comprises about
20 % of all lung cancers, EPSCC is uncommon, with an
overall incidence of approximately 0.1 to 0.4 % in
nonpulmonary sites.38 Approximately 1,000 new cases of
EPSCC are diagnosed yearly in the USA, which represents
2.5–5 % of SCC cases.37
Two cases of SCEC were first reported by McKeown in
1952. Although many consecutive cases have been reported
since then, only few large series of cases have been reported
in either China or other countries.41
, 42 The incidence of
SCEC between all esophageal malignancies is from 0.05 to
2.4 % in western populations, and this rate rises up to 7.6 %
in Chinese and Japanese literature.2
, 43, 44 The first largest
retrospective analysis has been carried out by Casas et al.
(1997), who analyzed 199 evaluable patients found in the
literature. They reported a male-to-female ratio of 1.57:1,
with 95 % of tumors situated in the mid- and lower esoph-
agus. One third of cases were mixed tumors with squamous
carcinoma. In our study, SCEC predominantly occurred in
males (2.4:1) at a median age of 57 years, with 89.7 % of
tumors located in mid- and lower thoracic esophagus, and
only 18.8 % of patients were with mixed tumors with
squamous or adencarcinoma, which was at variance with
other published literature on SCEC.
The most common symptoms were progressive dyspha-
gia and anorexia for nearly all patients. Retrosternal pain
(22.8 %) and swallow pain (15.6 %) were also observed in
advanced patients, respectively, which were identical to the
rate of esophageal squamous cell carcinoma without signif-
icant difference. This is because esophageal squamous cell
carcinoma is the most common cancer within esophageal
tumors in China.45
Our group observed a lower preoperative diagnostic rate of
6.3 %, in which most patients were pathologically confirmed
to have squamous cell carcinoma or poorly differentiated cell
carcinoma by preoperative esophagoscopy biopsy. The main
reason was that a small amount of tissues were picked for
endoscopic biopsy which could be limited for the diagnosis of
complex small cell carcinoma and sometimes incur difficulties
to differentiate SCEC from poorly differentiated squamous
cell carcinoma. Of the 322 patients with preoperative
esophagoscopy and biopsy, 86 cases were histologically diag-
nosed with poorly differentiated cell carcinoma or poorly
differentiated squamous cell carcinoma. Therefore, more tis-
sues and multipoint biopsy should be obtained under
Table 2 Univariate analysis of median survival for SCEC patients






Local treatment 10.1 (7.5–12)
Systemic treatment 16.8 (11–38)
Extensive disease
Local treatment 5.8 (4–7.5)
Systemic treatment 7.4 (7.2–8.5)
N0 lymph node negative, N+ lymph node positive
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esophagoscopy to carry out a diagnosis in a more accurate
fashion.
At present, the pathogenesis of SCEC is controversial and
remains speculative.37
, 44 A leading hypothesis is that SCEC
may originate from a pluripotent stem cell of the endoderm,
which may be partially differentiated into squamous cell
carcinoma and partially into adenocarcinoma or small cell
carcinoma because of the stimulation of different carcinogenic
agent. This is mainly due to the diversity of morphological,
immunohistological, and electron microscopic features of
SCEC, in addition to the coexistence of SCEC with
squamous cell carcinoma and /or adenocariconoma. In the
present study, we noted that 18.8 % of SCEC patients were
with elements of adenocariconoma or squamous cell
carcinoma, and this observation supported this hypothesis in a
positive fashion.
Limited data are available in the literature describing the
optimal management of patients with SCEC due to its lower
incidence rate and limited knowledge to the disease,37
, 38, 44
and there are no randomized controlled trials of treatment
and it is difficult to draw conclusions about effective
treatment from clinical series alone. In a multivariate
analysis performed, Casas et al. reported that in SCEC
patients, the median survival of patients who were treated
with local therapy only was 5 months. In patients who
received local treatment plus chemotherapy, the median
survival was 20 months. They concluded that the addition
of chemotherapy to local treatment should be considered as
standard treatment for limited disease of SCEC.2 A recent
retrospective study by Ding et al. reported different
treatments of limited-stage SCEC patients; combined mo-
dality treatment with and without chemotherapy yield 5-year
survival rates of 27.2 and 0 %, respectively, and associated
median survival times were 22 and 11 months, respectively
(p=0.001).46 But there was still some debate about whether
surgery or radiotherapy optimizes local treatment.3 Our data
indicated that the median survival time of LD patients who
received systemic treatment was 16.8 months, and 3-year
survival rate was 12.7 %, whereas that of LD patients who
received local treatment was only 10.1 months, and none
could survive for more than 3 years. The median survival of
ED patients who received systemic treatment was
7.4 months, whereas that of ED patients who received local
treatment was only 5.8 months. For either limited stage or
extensive stage, systemic treatment combined with surgical
resection appeared to be a good option. In the therapy of
SCEC, randomized, prospective, multicenter studies are
needed to identify optimal treatment modalities for SCEC.
Small cell lung cancer (SCLC) patients whose cancer can
be controlled outside the brain have a 60 % risk of devel-
oping central nervous system metastases within 2 to 3 years
after primary treatment,47
, 48 and can be considered for
administration of prophylactic cranial irradiation (PCI), the
risk of developing central nervous system metastases can be
reduced by more than 50 % by the administration of PCI in
doses of 24 Gy.48
, 49 But brain metastases in SCEC patients
were rarer than in SCLC.3
, 38, 50–54 Our data indicated that
brain metastases were uncommon in SCEC, and were
Table 3 Univariate analysis of survival rate for SCEC patients
No. of cases Survival rate (%,range)
1 year 2 year 3 year 5 year
Total 469 51.1 (41.3–67.2) 25.5 (16.1–38.5) 13.2 (6.4–23.3) 7.9 (3.5–12)
Lymph node metastasis
N0 45 31.1 (26.3–35.9) 11.4 (5.2–17.6) 5.3 (0–10.6)
N+ 84 77.3 (75–79.6) 42 (33.3–50.7) 28.6 (16.6–40.6)
VALSG stage
LD 176 62.1 (59.4–64.7) 31.2 (28.3–34.1) 12.5 (5.1–19.8)
ED 17 39.5 (33.3–45.6) 8.2 (0–16.4) 0
TNM stage
I 16 80.0 66.7 33.3
IIa 21 81.3 43.8 43.8
IIb 23 58.2 25.5 12.7
III 66 43.8 11.7 8.8
IV 25 47.6 17.9 6.0
Treatment
Local treatment 39 28.9 (20–37.9) 1.9 (0–3.8) 0
Systemic treatment 83 69.8 (50–89.5) 38.1 (21.4–57.6) 22.9 (11.7–40.0)
N0 lymph node negative, N+ lymph node positive, LD limited disease, ED extensive disease
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observed in only 2 of 185 patients.7
, 15 Because the
difference in incidence of brain metastasis at presentation
and during follow-up between SCEC and SCLC, efficacy
Of PCI for SCEC are lacking, we do not recommend a
routine usage for SCEC patients.
Conclusions
In summary, SCEC is a tumor characterized by high malig-
nancy and early metastasis; because of the lower incidence
rate of SCEC, it is hard to conduct a randomized controlled
trial so as to find a new therapeutic strategy. Despite rare
reports of long-term survivors of SCEC compared with
other esophageal cancer types, some patients were cured.
Although our retrospective analysis cannot provide defini-
tive conclusions on the optimal treatment modality for
SCEC, however, our results suggest that systemic treatment
combined with surgical resection plays a major role in the
therapy of SCEC, systemic therapy may be an effective
approach for the treatment of SCEC, and randomized, pro-
spective, multicenter studies are needed to identify optimal
treatment modalities for SCEC.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. McKeown F. Oat-cell carcinoma of the esophagus. J Pathol
Bacteriol 1952; 64:889–891 [PMID: 13000600]
2. Casas F, Ferrer F, Farrus B, et al. Primary small cell carcino-
ma of the esophagus: A Review of the literature with empha-
sis on therapy and prognosis. Cancer,1997,80:1366-
1372[PMID: 9338459].
3. Brenner B, Tang LH, Klimstra DS, et al. Small-Cell Carcinomas of
the Gastrointestinal Tract: A Review. J Clin Oncol, 2004,
22:2730–2739 [PMID: 15226341].
4. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging
Manual. 6th edn. New York: Springer 2002
5. Zelen M. Keynote address on biostatistics and data retrieval.
Cancer Chemother Rep 1973; 4: (Part 3)31-42[PMID:
4580860]
6. Van Der Gaast A, Verwey J, Prins E, et al. Chemotherapy as
treatment of choice in extrapulmonary undifferentiated small cell
carcinomas. Cancer 1990; 65:422-424[PMID: 1688727].
7. Song Y, Wang LH, He J, et al. Treatment and prognosis of primary
esophageal small cell carcinoma: a report of 151 cases. Ai zheng
(Chin), 2009, 28(3):303-307[PMID: 19619447]
8. Zhang L, Jiang T. Clinical analysis of 31 cases of primary small-
cell esophageal carcinoma. Chin J Clinic Oncol (Chin). 2009,
36(14):804–807
9. Zhu J, He JT, Li Q. Clinical features and effects of combined
therapy in 50 cases with primary esophageal small-cell carcinoma.
Chin J Clinic Oncol (Chin). 2007, 34(8):444–446.
10. Zhao XJ, Liu ZC, Zhao XY, et al. An analysis of treatment and
prognosis in 45 cases with small cell esophageal carcinoma. Bul-
letin of Chinese cancer. 2007, 16(2):81-82
11. Zou ML, Zuo FX, Xu J. The clinical analysis of 50 cases of
primary small cell carcinoma of esophagus. Chinese Journal of
Medical Guide. 2008, 10(8):1167–1168.
12. Feng W, Wang Z, Zheng X, et al. Clinical analysis of 67 cases with
primary small cell carcinoma of esophagus. Zhejiang Medical
Journal (Chin). 2007, 29(5):488–489
13. Chen J, Zhang DJ, LI HB, et al. A clinical study in undifferentiated
small cell carcinoma of the esophagus. China Clinical Practical
Medicine. 2009, 3(1):35–36
14. Chen QB, Wang HB, Zhang R, et al. The clinical analysis on small
cell carcinoma of the esophagus. The Practical Journal of Cancer
(Chin). 2007, 22(1):91–93
15. Li H, Liu SG, Liu XB, et al. Prognostic analysis of forty seven
patients with primary esophageal small cell carcinoma. Tumor
(Chin).2009,29(2):180–183
16. Li DS,Chen ZJ,Lin CF, et al. Clinical analysis of 54 cases with
primary small cell carcinoma of esophagus. The Journal of Practical
Medicine (Chin).2009,25(15):2522–2523
17. Guo M, Zhao YD, Jing LP. Pathological features of 72 cases with
primary small cell carcinoma of esophagus. The Practical Journal
of Cancer (Chin).2007, 22(3):318–319
18. Guo Y, Wang R, Yao JF, et al. Clinical analysis of 89 cases with
primary small cell carcinoma of esophagus. Clinical Medicine of
China.2005, 21(10):905–907.
19. Zhao HF, Zhao XJ, Tang P, et al. Clinical analysis of 67 cases with
primary esophageal small cell carcinoma. Journal of Tianjin
Medical University (Chin).2007, 13(3):387–389
20. Fang TysonBJ, Chen L.A retrospective analysis of primary esophageal
small cell carcinoma. Modern Oncology (Chin).2007, 15(6):791–793
21. Li CT, Zheng BX, Li JM. Clinical analysis of 25 cases with
primary small cell carcinoma of esophagus. Chin J Clinic Oncol
(Chin). 2005, 32(5):294–296.
22. Qian PD, Zhu J, Ma DW. Analysis of 26 patients with small cell
carcinoma of esophagus and review of the literature. Chinese
Clinical Oncology.2007, 12(3):207–210.
23. Wang HD, Qiu Y,Wu W,et al. Clinical observation and surgical
treatment of primary small cell carcinoma of esophagus: analysis
of 28 cases. Chongqing Medical Journal (Chin).2008, 37(4):353–
354
24. Duan HB, Wu HY, Su XD, et al. Clinical analysis of 33 cases of
primary esophageal small cell carcinoma. Chinese Journal of
Cancer.2007, 26(7):771–774.
25. Zhang YG,Wang ZS,Chi FS. Clinical analysis of 6 cases of
primary esophageal small cell carcinoma. Chinese Journal of
Misdiagnosis. 2006, 6(14):2781.
26. Liu SQ, Shi XT. Clinical analysis of 6 cases of primary esophageal
small cell carcinoma. Shandong Medical Journal (Chin) 2005,
45(6):8
27. Yang QH, Liu BX. Clinical analysis of 18 cases of primary
esophageal small cell carcinoma. Shandong Medical Journal
(Chin) 2007, 47(33):69–70.
28. Gong TQ, Jiang YG, Wang RW, et al. Surgical treatment for small
cell carcinoma of esophagus. Chongqing Medical Journal (Chin).
2005, 34 (4):532–533.
29. Yan XM, Sun L, Wang S. Primary esophageal small cell carcinoma
(a clinicopathological study of 11 cases). Journal of Basic and
Clinical Oncology (Chin).2009, 22(1):32–33
30. Zhou YQ. Clinical analysis of 13 cases of primary esophageal
small cell carcinoma. Journal of Practical Oncology (Chin).
2005, 19(6):429–431.
31. Kou WZ, Lu P, Niu Hr, et al. Clinical analysis of 16 cases with
primary esophageal small cell carcinoma. Medical Information
Section of Operative Surgery (Chin). 2008, 21(7):602–604
1186 J Gastrointest Surg (2013) 17:1181–1187
32. Zhao JM,Ding D,Liu FC, et al. Diagnosis and treatment of primary
esophageal small cell carcinoma: a report of 19 cases. Cancer
Research and Clinic (Chin).2005, 17(2):116-117
33. Liu ZH, Zhong J. Primary small cell carcinoma of esophagus in 34
patients. The Practical Journal of Cancer (Chin).2006, 21(6):612–
614,622
34. Chen WJ,Wang JZ,Lin JH, et al. Clinical analysis of 64 cases with
primary esophageal small cell carcinoma. Fujian Medical Journal
(Chin).2005, 27(4):49–51
35. Huang HT, Ma HT, He JK, et al. Clinical analysis of 12 patients
with small cell carcinoma of esophagus and review of the litera-
ture. Suzhou University Journal of Medical Science (Chin): 2007,
27(2):303–305
36. Mei XY,XuMQ,Wei DZ,et al. Surgical treatment and clinicopathologic
observation of primary esophageal small cell carcinoma. Anhui Med-
ical Journal (Chin).2009, 30(6):631–633
37. Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic
aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev
2009; 35:228-236 [PMID: 19068273]
38. Cicin I, Karagol H, Uzunoglu S, et al. Extrapulmonary small-cell
carcinoma compared with small-cell lung carcinoma: a retrospective
single-center study. Cancer. 2007; 110(5):1068-76[PMID: 17614337].
39. Li AF, Hsu HS, Hsu CY et al. A 20-year retrospective study
of small-cell carcinomas in Taiwan. J Surg Oncol. 2010;
102(5):497–502. [PMID: 20872953].
40. Brenner B, Shah MA, Gonen M, et al. Small-cell carcinoma of the
gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer,
2004; 90:1720-1726[PMID: 15150595].
41. Wang YG, Zhang RG, Zhang DW, et al. Primary esophageal small-
cell carcinoma. Chin J Oncol (Chin) 1999; 21(3):227–229.
42. 42 Li BQ, Wang GQ, Zhai Y, et al. Diagnosis and treatment of
primary small-cell carcinoma of the esophagus. Chin J Clinic
Oncol (Chin). 2003; 30(10):742–744
43. Caldwell CB, Bains MS, Burt M. Unusual malignant neoplasms of
the esophagus. Oat cell carcinoma, melanoma, and sarcoma. J
Thorac Cardiovasc Surg. 1991; 101:100–7. [PMID:1702494]
44. Sun KL, He J, Cheng GY, etal. Management of primary small cell
carcinoma of the esophagus. Chin Med J (Engl). 2007;
120(5):355–8. [PMID: 17376302].
45. Chen SB, Yang JS, Yang WP, et al. Treatment and prognosis of
limited disease primary small cell carcinoma of esophagus. Dis
Esophagus. 2011; 24(2):114–119 [PMID: 21040151].
46. Ding J, Ji J, Zhu W, et al. A retrospective study of different
treatments of limited-stage small-cell esophageal carcinoma
and associatedprognostic factor analysis. Dis Esophagus. 2013
Jan 14. [PMID: 23317069] [Epub ahead of print]
47. Nugent JL, Bunn PA Jr, Matthews MJ, et al. CNS metastases in
small cell bronchogenic carcinoma: increasing frequency and
changing pattern with lengthening survival. Cancer.1979;
44:1885–93 [PMID: 227582]
48. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial
irradiation for patients with small-cell lung cancer in complete
remission. Prophylactic cranial irradiation overview collaborative
group. N Engl J Med. 1999; 341:476–84. [PMID: 10441603]
49. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation
is indicated following complete response to induction therapy in
small cell lung cancer: results of a multicentre randomized trial.
United Kingdom Coordinating Committee for Cancer Research
(UKCCCR) and the European Organization for Research and
Treatment of Cancer (EORTC). Eur J Cancer. 1997; 33:1752–
8. [PMID: 9470828].
50. Viswanathan AN, Deavers MT, Jhingran A, et al. Small cell
neuroendocrine carcinoma of the cervix: outcome and patterns of
recurrence. Gynecol Oncol. 2004; 93:27–33. [PMID: 15047210].
51. Sengoz M, Abacioglu U, Salepci T, et al. Extrapulmonary small
cell carcinoma: multimodality treatment results. Tumori. 2003;
89:274–277 [PMID: 12908782].
52. Haider K, Shahid RK, Finch D, et al. Extrapulmonary small cell
cancer: a Canadian province’s experience. Cancer. 2006;
107:2262–2269[PM ID :16998932]
53. Ku GY, Minsky BD, Rusch VW, et al. Small-cell carcinoma of the
esophagus and gastroesophageal junction: review of the Memorial
Sloan-Kettering experience. Ann Oncol. 2008; 19(3):533–537
[PMID: 17947223].
54. Nakajima Y, Zenda S, Minashi K, et al. Non-surgical approach to
small cell carcinoma of the esophagus: does this rare disease have
the same tumor behavior as SCLC? Int J Clin Ocol. 2012;
17(6):610–5. [PMID: 22041926].
J Gastrointest Surg (2013) 17:1181–1187 1187
